Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 9/20 | 0.68 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | CLK1 | P49759 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1011884 | 0.82 | DYRK1A (0.71) | DYRK1AADORA1MAPTCLK1MEN1 | |
| SCHEMBL1040815 | 0.81 | DYRK1A (1.00) | DYRK1AADORA1MAPTCLK1MEN1 | |
| SCHEMBL13723979 | 0.81 | MAPT (0.74) | DYRK1AADORA1MAPTMEN1KMT2A | |
| SCHEMBL4914147 | 0.80 | MAPT (0.53) | MAPTMEN1KMT2ALMNAPARP1 | |
| SCHEMBL16254915 | 0.79 | DYRK1A (0.71) | DYRK1AADORA1MAPTMEN1KMT2A | |
| SCHEMBL30754208 | 0.79 | DYRK1A (0.71) | DYRK1AADORA1MAPTMEN1KMT2A | |
| SCHEMBL4250094 | 0.79 | DYRK1A (0.48) | DYRK1AADORA1MAPTCLK1 | |
| SCHEMBL15376502 | 0.77 | DYRK1A (1.00) | DYRK1AADORA1MAPTMEN1KMT2A | |
| SCHEMBL13878299 | 0.77 | DYRK1A (0.68) | DYRK1AADORA1MAPTCLK1MEN1 | |
| SCHEMBL1038556 | 0.76 | DYRK1A (0.78) | DYRK1AADORA1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7553848-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1725529-A1 | BIS BICYCLIC AMIDES AS VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS OF INFLAMMATORY AND NEUROPATIC PAIN | Amgen Inc. (US) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005070885-A1 | BIS BICYCLIC AMIDES AS VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS OF INFLAMMATORY AND NEUROPATIC PAIN | AMGEN INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| US-20050165046-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165046-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | DYRK1A 1411/4885ADORA1 1307/4885MAPT 824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.